Skip to main content
SpringerLink
Log in

LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

The hallucinogenic effects of lysergic acid diethylamide (LSD) have been attributed primarily to actions at serotonin receptors. A number of studies conducted in the 1970s indicated that LSD also has activity at dopamine (DA) receptors. These latter studies are difficult to interpret, however, because they were completed before the recognition of two pharmacologically distinct DA receptor subtypes, D1 and D2. The availability of subtype-selective ligands (e.g., the D1 antagonist SCH23390) and clonal cell lines expressing a homogeneous receptor population now permits an assessment of the contributions of DA receptor subtypes to the DA-mediated effects of LSD. The present study investigated the binding and functional properties of LSD and several lysergamide analogs at dopamine D1 and D2 receptors. Several of these compounds have been reported previously to bind with high affinity to serotonin 5HT2 (i.e.,3H-ketanserin) sites in the rat frontal cortex (K0.5 5–30 nM). All tested compounds also competed for both D1-like (3H-SCH 23390) and D2-like (3H-spiperone plus unlabeled ketanserin) DA receptors in rat striatum, with profiles indicative of agonists (n H<1.0). The affinity of LSD and analogs for D2 like receptors was similar to their affinity for 5HT2 sites. The affinity for D1 like receptors was slightly lower (2- to 3-fold), although LSD and several analogs bound to D1 receptors with affinity similar to the prototypical D1 partial agonist SKF38393 (K0.5 ca. 25 nM). A second series of experiments tested the binding and functional properties of LSD and selected analogs in C-6 glioma cells expressing the rhesus macaque D1A receptor. LSD and the analogs tested bound to C-6 mD1A cells with affinity and kinetics similar to those obtained in rat straitum. Additionally, LSD and selected analogs were able to increase cAMP accumulation, albeit only as partial agonists. Similar to the actions of SKF38393, they could stimulate, as well as block, DA-stimulated cAMP synthesis. These results represent the first clear demonstration of the interaction of LSD with DA D1 receptors, and provide a basis for evaluating the contribution of D1 receptors to the biobehavioral actions of LSD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Aghajanian GK (1994) Serotonin and the action of LSD in the brain. Psychiatr Ann 24:137–141

    Google Scholar 

  • Ahn HS, Makman MH (1979) Interaction of LSD and other hallucinogens with dopamine-sensitive adenylate cyclase in primate brain: regional differences. Brain Res 162:77–88

    Google Scholar 

  • Appel JB, White FJ, Holohean AM (1982) Analyzing mechanism(s) of hallucinogenic drug action with drug discrimination procedures, Neurosci Biobehav Rev 6:529–536

    Google Scholar 

  • Berger B (1992) Dopaminergic innervation of the frontal cerebral cortex: evolutionary trends and functional implications. Adv Neurol 57:525–544

    Google Scholar 

  • Berger B, Gaspar P, Verney C (1991) Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates. Trends Neurosci 14:21–27

    Google Scholar 

  • Boess FG, Martin IL (1994) Molecular biology of serotonin receptors. Neuropharmacology 33:275–317

    Google Scholar 

  • Braun AR, Chase TN (1986) Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors. Eur J Pharmacol 131:301–306

    Google Scholar 

  • Brewster WK, Nichols DE, Riggs RM, Mottola DM, Lovenberg TW, Lewis MH, Mailman RB (1990)trans-10,11-Dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. J Med Chem 33:1756–1764

    Google Scholar 

  • Burt DR, Creese I, Snyder SH (1976) Binding interactions of lysergic acid diethylamide and related agents with dopamine receptors in the brain. Mol Pharmacol 12:631–638

    Google Scholar 

  • Civelli O, Bunzow JR, Grandy DK, Zhou Q-Y, Van Tol HHM (1991) Molecular biology of the dopamine receptors Eur J Pharmacol 207:277–286

    Google Scholar 

  • Creese I, Burt DR, Snyder SH (1976) The dopamine receptor: differential binding ofd-LSD and related agents to agonist and antagonist states. Life Sci 17:1715–1720

    Google Scholar 

  • Christoph GR, Kuhn DM, Jacobs BL (1977) Electrophysiological evidence for a dopaminergic action of LSD: depression of unit activity in the substantia nigra of the rat. Life Sci 21:1585–1596

    Google Scholar 

  • DaPrada M, Saner A, Burkard WP, Bartholini G, Pletscher A (1975) Lysergic acid diethylamide: evidence for stimulation of cerebral dopamine receptors. Brain Res 94:67–73

    Google Scholar 

  • Dixon AK (1968) Evidence of catecholaminergic mediation in the “aberrant” behaviour induced by lysergic acid diethylamide (LSD) in the rat. Experienta 15:743–747

    Google Scholar 

  • Fog R, (1969) Stereotyped and non-stereotyped behaviour in rats induced by various stimulant drugs. Psychopharmacologia 14:299–304

    Google Scholar 

  • Freedman DX, Boggan WO (1982) Biochemical pharmacology of psychotomimetics. In: Hoffmeister F, Stille G (eds) Psychotropic agents: alcohol and psychotomimetics, psychotropic effects of central acting drugs, vol 55/III. Springer New York, pp 57–88

    Google Scholar 

  • Garau L, Govoni S, Stefanini E, Trabucchi M, Spano PF (1978) Dopamine receptors: pharmacological and anatomical evidence indicate that two distinct dopamine receptor populations are present in rat striatum. Life Sci 23:1745–1750

    Google Scholar 

  • Gingrich JA, Caron MG (1993) Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci 16:299–321

    Google Scholar 

  • Glennon R, Titeler M, McKenney JD (1984) Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 35:2505–2511

    Google Scholar 

  • Goldman-Rakic PS, Lidow MS, Smiley JF, Williams MS (1992) The anatomy of dopamine in monkey and human prefrontal cortex. J Neural Transm 36:S163–177

    Google Scholar 

  • Harper JF, Brooker G (1975) Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2'Oacetylation by acetic anhydride in aqueous solution. J Cyclic Nucl Res 1:207–218

    Google Scholar 

  • Heffner TG, Hartman JA, Seiden LS (1980) A rapid method for the regional dissection of the rat brain. Pharmacol Biochem Behav 13:453–456

    Google Scholar 

  • Hoffman AJ, Nichols DE (1985) Synthesis and LSD-like discrimantive stimulus properties in a series ofN(6)-alkyl norlysergic acidN,N-diethylamide derivatives. J Med Chem 28:1252–1255

    Google Scholar 

  • Holohean AM, White FJ, Appel JB (1982) Dopaminergic and serotonergic mediation of the discriminable effects of ergot alkaloids, Eur J Pharmacol 81:595–602

    Google Scholar 

  • Hu X-T, Wang RY (1988) Comparison of effects of D-1 and D-2 dopamine receptor agonists on neurons in the rat caudate-putamen: an electrophysiological study. J Neurosci 8:4340–4348

    Google Scholar 

  • Huang X, Marona-Lewicka D, Pfaff RC, Nichols DE (1994) Drug discrimination and receptor binding studies ofN-isopropyl lysergamide derivatives. Pharmacol Biochem Behav 47:667–673

    Google Scholar 

  • Joyce JN (1993) The dopamine hypothesis of schizophrenia: limbic interactions with serotonin and norepinephrine. Psychopharmacology 112:S16-S34

    Google Scholar 

  • Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277:93–96

    Google Scholar 

  • Kenakin TP (1987) Pharmacologic analysis of drug-receptor interaction Raven Press, New York

    Google Scholar 

  • Knoerzer TA, Nichols DE, Brewster WK, Watts VJ, Mottola DM, Mailmann RB (1994) Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist. J Med Chem 37:2453–2460

    Google Scholar 

  • Leysen JE, Janssen PMF, Schotte A, Luyten WHML, Megens AAHP (1993) Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology 112:S40-S54

    Google Scholar 

  • Lovenberg TW, Brewster WK, Mottola DM, Lee RC, Riggs RM, Nichols DE, Lewis MH, Mailman RB (1989). Dihydrexidine, a novel selective high potency full dopamine D1 receptor agonist. Eur J Pharmacol 166:111–113

    Google Scholar 

  • McKenna DJ, Repke DB, Lo L, Peroutka SJ (1990) Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes, Neuropharmacology 29:193–198

    Google Scholar 

  • McPherson GA (1985) Analysis of radioligand binding experiments. A collection of computer programs for the IBM PC. J Pharmacol Methods 14:213–228

    Google Scholar 

  • McQuadde RD, Duffy RA, Coffin VL, Barnett A (1992) In vivo binding to dopamine receptors: a correlate of potential antipsychotic activity. Eur J Pharmacol 215:29–34

    Google Scholar 

  • Machida CA, Searles RP, Nipper V, Brown JA, Kozell LB, Neve KA (1992) Molecular cloning and expression of the rhesus macaque D1 dopamine receptor gene. Mol Pharmacol 41:652–659

    Google Scholar 

  • May T, Sugawa M (1993) Altered dopamine receptor mediated signal transduction in the striatum of aged rats. Brain Res 604:106–111

    Google Scholar 

  • Meltzer HY, Nash JF (1991) Effects of antipsychotic drugs on serotonin receptors. Pharmacol Rev 43:587–604

    Google Scholar 

  • Middlemiss DN, Fozard JR (1983) 8-Hydroxy-2-(di-n-propylamino)-tetralin discriminates between subtypes of the 5-HT1 recognition site. Eur J Pharmacol 90:151–153

    Google Scholar 

  • Mokler DJ, Commissaris RL, Warner MR, Rech RH (1983) Blockade of the behavioral effects of lysergic acid diethylamide, 2,5-dimethoxy-4-methylamphetamine, quipazine and lisuride by 5-hydroxytryptamine antagonists. J Pharmacol Exp Ther 22:557–562

    Google Scholar 

  • Mottola DM, Brewster WK, Cook LL, Nichols DE, Mailman RB (1992) Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. J Pharmacol Exp Ther 262:383–393

    Google Scholar 

  • Nichols DE, Oberlender R, McKenna DJ (1991) Stereochemical aspects of hallucinogenesis. In: Watson R (ed). Biochemistry and physiology of substance abuse. CRC Press, Boca Raton Fl., pp. 1–39

    Google Scholar 

  • Oberlender R, Pfaff RC, Johnson MP, Huang X, Nichols DE (1992) Stereoselective LSD-like activity ind-lysergic acid amides of (R)- and (S)-2-aminobutane. J Med Chem 35:203–211

    Google Scholar 

  • Patel A, Linden J (1988) Purification of125I-labelled succinyl cyclic nucleotide tyrosine methyl esters by high-performance liquid chromatography. Anal Biochem 168:417–420

    Google Scholar 

  • Persson S-A (1977) The effect of LSD and 2-bromo LSD on the striatal DOPA accumulation after decarboxylase inhibition in rats. Eur J Pharmacol 43:73–83

    Google Scholar 

  • Persson S-A (1978) Effects of LSD and BOL on the catecholamine synthesis and turnover in various brain regions. Psychopharmacology 59:113–116

    Google Scholar 

  • Pieri L, Keller HH, Burkard W, Da Prada M (1978) Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis. Nature 272:278–280

    Google Scholar 

  • Pieri L, Pieri M, Haefely W (1974) LSD as an agonist of dopamine receptors in the striatum. Nature 252:586–588

    Google Scholar 

  • Pifl C, Reither H, Hornykiewicz O (1991) Lower efficacy of the dopamine D1 agonist, SKF38393, to stimulate adenylyl cyclase activity in primate than in rodent striatum. Eur J Pharmacol 202:273–276

    Google Scholar 

  • Sawaguchi T, Goldman-Rakic PS (1991) D1dopamine receptors in prefrontal cortex: involvement in working memory. Science 251:947–950

    Google Scholar 

  • Sanders-Bush E, Breeding M (1991) Choroid plexus epithelial cells in primary culture: a model of 5HT1C receptor activation by hallucinogenic drugs. Psychopharmacology 105:340–346

    Google Scholar 

  • Sibley DR, Monsma FJ (1990) Molecular biology of dopamine receptors. Trends Pharmacol Sci 13:61–69

    Google Scholar 

  • Spano PF, Kumakura K, Tonon GC, Govoni S, Trabucchi M (1975) LSD and dopamine-sensitive adenylate-cyclase in various rat brain areas. Brain Res 93:164–167

    Google Scholar 

  • Stoof JC, Kebabian JW (1981) Opposing roles for D-1 and D-2 dopamine receptors in efflux of cAMP from rat neostriatum. Nature 294:366–368

    Google Scholar 

  • Titeler M, Lyon RA, Glennon RA (1988) Radioligand binding evidence implicates the brain 5HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology 94:213–216

    Google Scholar 

  • Trulson Me, Stark AD, Jacobs BJ (1977) Comparative effects of hallucinogenic drugs on rotational behavior in rats with unilateral 6-hydroxydopamine lesions. Eur J Pharmacol 44:113–119

    Google Scholar 

  • Von Hungen K, Robers S, Hill DF (1974) LSD as an agonist and antagonist at central dopamine receptors. Nature 252:588–589

    Google Scholar 

  • Walters JR, Baring MD, Lakoski JM (1979) Effects of ergolines on dopaminergic and serotonergic single unit activity. In: Fuxe K, Calne DB (eds) Dopaminergic ergot derivatives and motor function. Pergamon Press, New York, pp 207–221

    Google Scholar 

  • Watts VJ, Lawler CP, Gonzales AJ, Zhou Q-Y, Civelli O, Nichols DE, Mailman RB (1993) Efficacy of D1 dopamine receptor agonists: the role of spare receptors. Soc Neurosci Abstr 18:75

    Google Scholar 

  • White FJ (1986) Comparative effects of LSD and lisuride: clues to specific hallucinogenic drug actions. Pharmacol Biochem Behav 24:365–379

    Google Scholar 

  • Wyrick S, Mailman RB (1985) Tritium labelled (±)-7-chloro-8-hydrozy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SCH23390). J Label Comp Radiopharmac 22:189–195

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, University of North Carolina School of Medicine, 27599-7250, Chapel Hill, NC, USA

    V. J. Watts & R. B. Mailman

  2. Department of Psychiatry, University of North Carolina School of Medicine, 27599-7250, Chapel Hill, NC, USA

    R. B. Mailman

  3. Brain and Development Research Center, University of North Carolina School of Medicine, 27599-7250, Chapel Hill, Nc, USA

    V. J. Watts, R. B. Mailman & C. P. Lawler

  4. Curriculum in Toxicology, University of North Carolina School of Medicine, 27599-7250, Chapel Hill, NC, USA

    R. B. Mailman & C. P. Lawler

  5. Veterans Affairs Medical Center, 97201, Portland, OR, USA

    K. A. Neve

  6. Department of Medicinal Chemistry and Pharmacognosy, School of Pharmacy and Pharmacal Sciences, Purdue University, 47907, West Lafayette, IN, USA

    D. E. Nichols

Authors
  1. V. J. Watts
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. B. Mailman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. P. Lawler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. A. Neve
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. E. Nichols
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Watts, V.J., Mailman, R.B., Lawler, C.P. et al. LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors. Psychopharmacology 118, 401–409 (1995). https://doi.org/10.1007/BF02245940

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02245940

Key words

Search

Navigation